Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael I Benhamou

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
JACS Au|August 29, 2025
Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuRLiann Kassabri, Raphael I Benhamou
Heliyon|January 20, 2025
Leveraging RIBOTAC technology: Fluorescent RNase L probes for live-cell imaging and function analysisElias Khaskia, Raphael I Benhamou
Non-Coding RNA|March 25, 2024
Targeting MicroRNAs with Small MoleculesKisanet Tadesse, Raphael I Benhamou
STAR Protocols|June 15, 2025
Protocol for evaluating compound uptake and RNase L co-localization in live cells using fluorescence-based binding, competition assay, and confocal microscopyElias Khaskia, Raphael I Benhamou
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 6, 2025
RNA G-Quadruplex RIBOTAC-Mediated Targeted Degradation of lncRNA TERRAElias Khaskia, Dipak Dahatonde, Raphael I Benhamou
Expert Opinion on Drug Discovery|June 12, 2023
Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)Salma Haj-Yahia, Arijit Nandi, Raphael I Benhamou
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 4, 2016
Antifungal Imidazole-Decorated Cationic Amphiphiles with Markedly Low Hemolytic ActivityRaphael I Benhamou, Kfir B Steinbuch, Micha Fridman
Expert Opinion on Drug Discovery|April 6, 2025
Advancing target validation with PROTAC technologyM Leora Spitz, Aseel Kashkush, Raphael I Benhamou
Angewandte Chemie (International Ed. in English)|March 26, 2018
Localizing Antifungal Drugs to the Correct Organelle Can Markedly Enhance their EfficacyRaphael I Benhamou, Maayan Bibi, Judith Berman, et al.
ACS Pharmacology & Translational Science|September 19, 2025
Development of PROTAC-Based Strategies for Cannabinoid Receptor Type 1 (CB<sub>1</sub>R) Degradation in CancerAseel Kashkush, Kisanet Tadesse, Judith Furth-Lavi, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
JACS Au|August 29, 2025
Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuRLiann Kassabri, Raphael I Benhamou
Heliyon|January 20, 2025
Leveraging RIBOTAC technology: Fluorescent RNase L probes for live-cell imaging and function analysisElias Khaskia, Raphael I Benhamou
Non-Coding RNA|March 25, 2024
Targeting MicroRNAs with Small MoleculesKisanet Tadesse, Raphael I Benhamou
STAR Protocols|June 15, 2025
Protocol for evaluating compound uptake and RNase L co-localization in live cells using fluorescence-based binding, competition assay, and confocal microscopyElias Khaskia, Raphael I Benhamou
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 6, 2025
RNA G-Quadruplex RIBOTAC-Mediated Targeted Degradation of lncRNA TERRAElias Khaskia, Dipak Dahatonde, Raphael I Benhamou
Expert Opinion on Drug Discovery|June 12, 2023
Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)Salma Haj-Yahia, Arijit Nandi, Raphael I Benhamou
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 4, 2016
Antifungal Imidazole-Decorated Cationic Amphiphiles with Markedly Low Hemolytic ActivityRaphael I Benhamou, Kfir B Steinbuch, Micha Fridman
Expert Opinion on Drug Discovery|April 6, 2025
Advancing target validation with PROTAC technologyM Leora Spitz, Aseel Kashkush, Raphael I Benhamou
Angewandte Chemie (International Ed. in English)|March 26, 2018
Localizing Antifungal Drugs to the Correct Organelle Can Markedly Enhance their EfficacyRaphael I Benhamou, Maayan Bibi, Judith Berman, et al.
ACS Pharmacology & Translational Science|September 19, 2025
Development of PROTAC-Based Strategies for Cannabinoid Receptor Type 1 (CB<sub>1</sub>R) Degradation in CancerAseel Kashkush, Kisanet Tadesse, Judith Furth-Lavi, et al.
Pageof 4